{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:07:51Z","timestamp":1791050871179,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3533,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008126","name":"Dana-Farber\/Harvard Cancer Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008126","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Excellence in Lung Cancer"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P20 CA90578"],"award-info":[{"award-number":["P20 CA90578"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 CA90687"],"award-info":[{"award-number":["R01 CA90687"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1093\/annonc\/mdp377","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T03:35:10Z","timestamp":1255491310000},"page":"884-894","source":"Crossref","is-referenced-by-count":59,"title":["Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours"],"prefix":"10.1016","volume":"21","author":[{"given":"D.S.","family":"Boss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.K.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.D.","family":"Amakye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Swaisland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Midgley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ranson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Danson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"Chirieac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp377_bb0010","first-page":"7","article-title":"Control of the G1\/S transition","volume":"29","author":"Reed","year":"1997","journal-title":"Cancer Surv"},{"key":"10.1093\/annonc\/mdp377_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/MCB.18.2.753","article-title":"Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes","volume":"18","author":"Lundberg","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mdp377_bb0020","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(00)81519-6","article-title":"Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1","volume":"98","author":"Harbour","year":"1999","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdp377_bb0025","first-page":"305","article-title":"The cell cycle kinases","volume":"5","author":"Pines","year":"1994","journal-title":"Semin Cancer Biol"},{"key":"10.1093\/annonc\/mdp377_bb0030","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"10.1093\/annonc\/mdp377_bb0035","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp377_bb0040","doi-asserted-by":"crossref","first-page":"9408","DOI":"10.1200\/JCO.2005.01.5594","article-title":"Targeting the cell cycle: a new approach to cancer therapy","volume":"23","author":"Schwartz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp377_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1359-6349(03)80014-9","article-title":"Novel approaches in oncology at AstraZeneca","volume":"1","author":"Wheeler","year":"2003","journal-title":"Eur J Cancer Suppl"},{"key":"10.1093\/annonc\/mdp377_bb0050","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1158\/0008-5472.CAN-05-1769","article-title":"AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9","volume":"66","author":"Cai","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp377_bb0055","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1535-7163.MCT-05-0205","article-title":"The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor","volume":"5","author":"Byth","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdp377_bb0060","doi-asserted-by":"crossref","first-page":"9270","DOI":"10.1158\/0008-5472.CAN-06-1758","article-title":"Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells","volume":"66","author":"Cai","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp377_bb0065","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00280-006-0371-x","article-title":"A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers","volume":"60","author":"Camidge","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdp377_bb0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00280-006-0387-2","article-title":"A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers","volume":"60","author":"Camidge","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdp377_bb0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp377_bb0080","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-04-0229","volume":"10","author":"Haddad","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp377_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm0297-231","article-title":"Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas","volume":"3","author":"Loda","year":"1997","journal-title":"Nature Med"},{"key":"10.1093\/annonc\/mdp377_bb0090","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-08-1748","article-title":"Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer","volume":"15","author":"Hsieh","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp377_bb0095","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.2000.18.2.371","article-title":"Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago phase II consortium study","volume":"18","author":"Stadler","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp377_bb0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3816\/CLC.2008.n.024","article-title":"Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer","volume":"9","author":"George","year":"2008","journal-title":"Clin Lung Cancer"},{"key":"10.1093\/annonc\/mdp377_bb0105","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1158\/1078-0432.CCR-04-2566","article-title":"Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points","volume":"11","author":"Bible","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp377_bb0110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nm1047","article-title":"Bioluminescent imaging of Cdk2 inhibition in vivo","volume":"10","author":"Zhang","year":"2004","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdp377_bb0115","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1002\/j.1460-2075.1996.tb01097.x","article-title":"The consensus motif for phosphorylation by cyclin D1-cdk4 is different from that for phosphorylation by cyclin A\/E-cdk2","volume":"15","author":"Kitagawa","year":"1996","journal-title":"EMBO J"},{"key":"10.1093\/annonc\/mdp377_bb0120","doi-asserted-by":"crossref","first-page":"12738","DOI":"10.1074\/jbc.272.19.12738","article-title":"Differential phosphorylation of the retinoblastoma protein by G1\/S cyclin-dependent kinases","volume":"272","author":"Zarkowska","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdp377_bb0125","first-page":"4320","article-title":"Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region","volume":"60","author":"Brantley","year":"2000","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419389355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419389355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/4\/884\/13782632\/mdp377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:21:09Z","timestamp":1624519269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419389355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0923753419389355"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp377","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}